QLC5508

DRUG5 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Advanced Prostate CancerAdvanced Solid TumorEsophageal Squamous Cell Carcinoma (ESCC)Extensive-stage Small Cell Lung CancerProstate Cancer

Phase 1

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

RecruitingNCT07198633

Qilu Pharmaceutical Co., Ltd.Advanced Prostate Cancer

Start: 2025-11-05End: 2027-12-01Target: 212Updated: 2026-06-02

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

RecruitingNCT07256782

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2025-10-24End: 2028-05-31Target: 444Updated: 2025-12-01

Phase 3

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

RecruitingNCT07463573

Qilu Pharmaceutical Co., Ltd.Esophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-04-20End: 2029-07-05Target: 466Updated: 2026-04-24

QLC5508 in Participants With Metastatic Prostate Cancer

Not yet recruitingNCT07632690

Qilu Pharmaceutical Co., Ltd.Prostate Cancer

Start: 2026-06-20End: 2030-11-20Target: 700Updated: 2026-06-08

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer

Not yet recruitingNCT07802821

Qilu Pharmaceutical Co., Ltd.Extensive-stage Small Cell Lung Cancer

Start: 2026-10-15End: 2030-06-15Target: 556Updated: 2026-09-03